Articles tagged with: Carfilzomib
The National Comprehensive Cancer Network (NCCN) recently released an updated version of its guidelines for the diagnosis and treatment of multiple myeloma.
The most notable change to the guidelines is the addition of Kyprolis (carfilzomib), in combination with Revlimid (lenalidomide) and dexamethasone (Decadron), as an alternative treatment option for newly diagnosed myeloma patients eligible for a stem cell transplant.
The guidelines also now list Pomalyst (pomalidomide), in combination with dexamethasone, as a preferred salvage treatment for myeloma.
NCCN guidelines are followed closely by physicians and by many …
Results from a Phase 1b clinical trial indicate that Kyprolis in combination with Revlimid and low-dose dexamethasone is effective and safe for relapsed multiple myeloma patients.
Moreover, at the higher doses of Kyprolis and Revlimid tested during the trial, a greater share of patients responded to treatment than was the case in a trial testing Revlimid, Velcade, and dexamethasone in a similar patient population.
In addition, noticeably fewer cases of peripheral neuropathy – that is, pain, tingling, or loss of sensation in the extremities – were observed in the current …
A new study provides the first detailed look at Kyprolis when it is used in multiple myeloma patients with kidney damage.
The focus of the study is on determining how Kyprolis (carfilzomib) is processed in the bodies of myeloma patients and, in particular, if the drug is processed differently depending on how much kidney damage a patient has.
In addition, the study investigates whether kidney damage affects how often patients experience side effects when treated with Kyprolis.
Based on the results of their study, the authors conclude that Kyprolis’s dosing …
This year’s meeting of the American Society of Hematology (ASH) was held December 8 through 11 in Atlanta.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting. After the meeting concluded, The Beacon began publishing in-depth articles about the key research findings.
This article, however, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did …
ARRY-520 is one of several potential new anti-myeloma agents that was highlighted at the American Society of Hematology (ASH) annual meeting earlier this week.
Initial results from two clinical trials show promise for ARRY-520, alone or in combination with other myeloma drugs, as a therapeutic option for heavily pretreated multiple myeloma patients.
“ARRY-520 shows promising activity in combination with dexamethasone in heavily pretreated myeloma patients,” said Dr. Jatin Shah, from the MD Anderson Cancer Center in Houston and lead investigator of both studies.
Based on their findings, the …